celares - Biosynth’s Post

🌟 The Evolution of Chemical Development at GSK: Embracing SYNTHIA™ for Unprecedented Advancements! 🌟 🔬 In a captivating presentation, John Jin Lim from GSK sheds light on the pivotal shift from using a previous CASD program (referred to as Program One) to the game-changing adoption of SYNTHIA™ Retrosynthesis Software. 🛠️ John candidly discusses the challenges faced with Program One, citing issues with clunky functionality, subpar literature references, and cumbersome output navigation. These limitations prompted GSK to embark on a comprehensive evaluation of multiple CASD programs, including SYNTHIA™, based on five crucial criteria. 📊 The evaluation criteria encompassed the ease of operation, generation and analysis of output, improved interface, procurement and cost information, ranking and filtering disconnections, and the provision of relevant and easily accessible literature. SYNTHIA™ emerged as the frontrunner, boasting the least amount of red marks in the evaluation. 🚀 Notably, SYNTHIA™ demonstrated its prowess by reducing step count for seven out of nine compounds with a Medchem route, proposing selective routes for compounds requiring chiral separations, and offering unique ideas that complemented the staff's input. This exceptional performance led to the decision to allocate further investments to SYNTHIA™ in 2021, signifying GSK's confidence in its potential to revolutionize chemical development. 🔗 Dive deeper into the full webinar to grasp the transformative impact of SYNTHIA™ on GSK's chemical development landscape, propelling the organization toward unparalleled efficiency and innovation. #ChemicalDevelopment #Innovation #GSK #SYNTHIA #Retrosynthesis #ChemicalEngineering #WebinarInsights #TeamMerck

🌟 The Evolution of Chemical Development at GSK: Embracing SYNTHIA™ for Unprecedented Advancements! 🌟 🔬 In a captivating presentation, John Jin Lim from GSK sheds light on the pivotal shift from using a previous CASD program (referred to as Program One) to the game-changing adoption of SYNTHIA™ Retrosynthesis Software. 🛠️ John candidly discusses the challenges faced with Program One, citing issues with clunky functionality, subpar literature references, and cumbersome output navigation. These limitations prompted GSK to embark on a comprehensive evaluation of multiple CASD programs, including SYNTHIA™, based on five crucial criteria. 📊 The evaluation criteria encompassed the ease of operation, generation and analysis of output, improved interface, procurement and cost information, ranking and filtering disconnections, and the provision of relevant and easily accessible literature. SYNTHIA™ emerged as the frontrunner, boasting the least amount of red marks in the evaluation. 🚀 Notably, SYNTHIA™ demonstrated its prowess by reducing step count for seven out of nine compounds with a Medchem route, proposing selective routes for compounds requiring chiral separations, and offering unique ideas that complemented the staff's input. This exceptional performance led to the decision to allocate further investments to SYNTHIA™ in 2021, signifying GSK's confidence in its potential to revolutionize chemical development. 🔗 Dive deeper into the full webinar to grasp the transformative impact of SYNTHIA™ on GSK's chemical development landscape, propelling the organization toward unparalleled efficiency and innovation. #ChemicalDevelopment #Innovation #GSK #SYNTHIA #Retrosynthesis #ChemicalEngineering #WebinarInsights #TeamMerck

🌟 The Evolution of Chemical Development at GSK: Embracing SYNTHIA™ for Unprecedented Advancements! 🌟 🔬 In a captivating presentation, John Jin Lim from GSK sheds light on the pivotal shift from using a previous CASD program (referred to as Program One) to the game-changing adoption of SYNTHIA™ Retrosynthesis Software. 🛠️ John candidly discusses the challenges faced with Program One, citing issues with clunky functionality, subpar literature references, and cumbersome output navigation. These limitations prompted GSK to embark on a comprehensive evaluation of multiple CASD programs, including SYNTHIA™, based on five crucial criteria. 📊 The evaluation criteria encompassed the ease of operation, generation and analysis of output, improved interface, procurement and cost information, ranking and filtering disconnections, and the provision of relevant and easily accessible literature. SYNTHIA™ emerged as the frontrunner, boasting the least amount of red marks in the evaluation. 🚀 Notably, SYNTHIA™ demonstrated its prowess by reducing step count for seven out of nine compounds with a Medchem route, proposing selective routes for compounds requiring chiral separations, and offering unique ideas that complemented the staff's input. This exceptional performance led to the decision to allocate further investments to SYNTHIA™ in 2021, signifying GSK's confidence in its potential to revolutionize chemical development. 🔗 Dive deeper into the full webinar to grasp the transformative impact of SYNTHIA™ on GSK's chemical development landscape, propelling the organization toward unparalleled efficiency and innovation. #ChemicalDevelopment #Innovation #GSK #SYNTHIA #Retrosynthesis #ChemicalEngineering #WebinarInsights #TeamMilliporeSigma

🌟 The Evolution of Chemical Development at GSK: Embracing SYNTHIA™ for Unprecedented Advancements! 🌟 🔬 In a captivating presentation, John Jin Lim from GSK sheds light on the pivotal shift from using a previous CASD program (referred to as Program One) to the game-changing adoption of SYNTHIA™ Retrosynthesis Software. 🛠️ John candidly discusses the challenges faced with Program One, citing issues with clunky functionality, subpar literature references, and cumbersome output navigation. These limitations prompted GSK to embark on a comprehensive evaluation of multiple CASD programs, including SYNTHIA™, based on five crucial criteria. 📊 The evaluation criteria encompassed the ease of operation, generation and analysis of output, improved interface, procurement and cost information, ranking and filtering disconnections, and the provision of relevant and easily accessible literature. SYNTHIA™ emerged as the frontrunner, boasting the least amount of red marks in the evaluation. 🚀 Notably, SYNTHIA™ demonstrated its prowess by reducing step count for seven out of nine compounds with a Medchem route, proposing selective routes for compounds requiring chiral separations, and offering unique ideas that complemented the staff's input. This exceptional performance led to the decision to allocate further investments to SYNTHIA™ in 2021, signifying GSK's confidence in its potential to revolutionize chemical development. 🔗 Dive deeper into the full webinar to grasp the transformative impact of SYNTHIA™ on GSK's chemical development landscape, propelling the organization toward unparalleled efficiency and innovation. #ChemicalDevelopment #Innovation #GSK #SYNTHIA #Retrosynthesis #ChemicalEngineering #WebinarInsights #TeamMilliporeSigma

🌟 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬 𝐟𝐫𝐨𝐦 𝐁𝐢𝐨𝐋𝐢𝐧𝐤 𝐋𝐢𝐟𝐞𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬! 🌟 We are thrilled to announce a major upgrade to our laboratory with the addition of the 𝐌𝐚𝐥𝐯𝐞𝐫𝐧 𝐌𝐚𝐬𝐭𝐞𝐫𝐬𝐢𝐳𝐞𝐫 3000! 🎉 At BioLink Life Sciences, we constantly strive to enhance our capabilities and stay at the forefront of scientific innovation. The #Malvern #Mastersizer 3000, a state-of-the-art particle size analyzer, is the latest addition to our arsenal of advanced research tools. 🔬 𝐖𝐡𝐲 𝐭𝐡𝐞 𝐌𝐚𝐥𝐯𝐞𝐫𝐧 𝐌𝐚𝐬𝐭𝐞𝐫𝐬𝐢𝐳𝐞𝐫 3000? The Malvern Mastersizer 3000 is renowned for its precision and efficiency in particle size analysis, making it an invaluable asset for a wide range of applications, including pharmaceuticals, biotechnology, and materials science. Here’s how this cutting-edge technology will benefit our work: ✒ 𝑼𝒏𝒎𝒂𝒕𝒄𝒉𝒆𝒅 𝑨𝒄𝒄𝒖𝒓𝒂𝒄𝒚: Delivers highly accurate particle size distribution data, ensuring the quality and consistency of our research. ✒ 𝑹𝒂𝒑𝒊𝒅 𝑨𝒏𝒂𝒍𝒚𝒔𝒊𝒔: With its quick processing capabilities, we can achieve faster turnaround times, enhancing our project efficiency and client service. ✒ 𝑾𝒊𝒅𝒆 𝑽𝒆𝒓𝒔𝒂𝒕𝒊𝒍𝒊𝒕𝒚: Capable of analyzing various sample types and sizes, making it adaptable to diverse research needs. 🌐 𝐖𝐡𝐚𝐭 𝐃𝐨𝐞𝐬 𝐓𝐡𝐢𝐬 𝐌𝐞𝐚𝐧 𝐟𝐨𝐫 𝐎𝐮𝐫 𝐂𝐥𝐢𝐞𝐧𝐭𝐬? Integrating the Malvern Mastersizer 3000 into our laboratory empowers BioLink to provide even more precise and reliable data. This advancement allows our clients to make well-informed decisions, accelerating their research and development processes with greater confidence. This upgrade underscores our commitment to investing in state-of-the-art technologies that elevate our research capabilities. By embracing the latest scientific advancements, BioLink Lifesciences continues to lead in the life sciences sector, driving innovation and discovery. We are excited about the possibilities this new addition brings and look forward to the groundbreaking discoveries and advancements it will enable. Thank you for your continued support and partnership! #BioLinkLifesciences #LabUpgrade #MalvernMastersizer3000 #Biolink #ParticleSizeAnalysis #ScientificInnovation #ResearchAndDevelopment #LifeSciences #pharmaworld #pharmaceuticals #analyticaltesting #formulation #cmc #CRO #lifesciences #Biolinklabupgrade

Coming this January... Dive into the world of Resolian with our upcoming video series featuring our CEO Patrick Bennett!   Explore the history that shaped Resolian and get a sneak peek into our future plans.   🔍 Chapter 1 - "We Are Resolian" Discover the journey behind our recent rebranding directly from our CEO, Patrick Bennett, in an insightful interview with Chris Conner from Life Science Marketing Radio.   🎬 Watch the video below 👇   Get ready for an exclusive look into the heart of Resolian, as we share our resolution to be one of the best laboratories globally committed to our purpose and mission in serving customers and our scientific staff.   #Resolian #VideoSeries #CompanyCulture #LabInnovation #WatchNow #Bioanalytics #bioanalyticalservices #AnalyticalSciences #ContractResearchOrganization #CRO #biotech #lifescience #pharma #drugdevelopment 🎥

For all analysts in the #biotech, #pharmaceutical and #researchanddevelopment industry, Foxx's Autofil is a must have for your labs. Made of polypropylene or BPA-free polystyrene material, these top-quality units are engineered for next-generation purification of solvents for research and analytical applications, including cell and tissue culture. #filtrationsolutions #pharmaceuticalindustry #innovation https://lnkd.in/guUDYSX4

On behalf of BioStem Technologies, we wish you a happy Mother’s Day! #BSEM #BioStem #BioStemTechnologies #AdvancedWoundCare #Biotech #CuttingEdge #RegenerativeMedicine BioStem Technologies, Inc. (OTC: BSEM) is a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care. Visit https://lnkd.in/ecGZ8JBe to learn more about us! Here are some fun facts about Mother’s Day: 1.) More calls are made on Mother's Day than any other day of the year. 2. The moniker 'Mom' comes from babies. The first thing most babies can vocalize is the 'ma' sound, which is why in almost every language the word for mother begins with the letter 'M' or is some iteration of the 'ma' sound. 3. The history of American Mother's Day starts with peacemaker Ann Jarvis. During and following the Civil War, Ann Jarvis made a concerted effort to foster friendship and community between the mothers on both sides of the war. She started a committee in 1868 that established the first glimmer of today's holiday: "Mother's Friendship Day."

🌟 Testimonial Spotlight – Lars Ole-Gerlach, Former Executive VP R&D, EpiTherapeutics ApS We are excited to share another success story from one of our previous clients, EpiTherapeutics ApS. Feedback from clients like Lars assists us in guiding our business towards innovation, fueling our passion for science and further elevating our standards⚛ 🗣“Our collaboration with CanAm Bioresearch has been vital for us. They are the best medicinal chemistry CRO we have ever worked with. They are fast in generating analogs in several chemotypes, very flexible on expanding the group as needed, and know when and how to take short-cuts to save time without sacrificing quality.” Ready to discover how we drive our clients’ success? Head over to our website to read more success stories from clients like Lars: https://lnkd.in/ebVwMwHi _______ #canambioresearch #canaminnovation #sucessstories #clienttestimonial #customersuccess #Innovation 

📣 GenoFAB Inc. is excited to announce the development of a new plasmid distribution service that will improve the quality of plasmid documentation, streamline licensing, clarify intellectual property status, and enhance quality control processes. To ensure the service meets the needs of potential users, we want to hear from: - Biotech companies looking to access plasmids from third parties - Academic and corporate plasmid developers interested in licensing their plasmids for research purposes - Biotech companies needing to control plasmid distribution with business partners Are you interested in early access to GenoFAB's new plasmid distribution service? Share your plasmid purchasing and distribution methods by filling out this form: https://lnkd.in/gUBxcheJ #biotechnology #syntheticbiology #synbio #security #cyberbiosecurity #reproducibility #intellectualproperty #mta #plasmids #bioengineering #molecularbiology #protein